Christopher Navara to Enzyme Inhibitors
This is a "connection" page, showing publications Christopher Navara has written about Enzyme Inhibitors.
Connection Strength
0.335
-
Navara CS. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy. Curr Pharm Des. 2004; 10(15):1739-44.
Score: 0.199
-
Constantinescu D, Csoka AB, Navara CS, Schatten GP. Defective DSB repair correlates with abnormal nuclear morphology and is improved with FTI treatment in Hutchinson-Gilford progeria syndrome fibroblasts. Exp Cell Res. 2010 Oct 15; 316(17):2747-59.
Score: 0.078
-
Malaviya R, Chen CL, Navara C, Malaviya R, Liu XP, Keenan M, Waurzyniak B, Uckun FM. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec; 295(3):912-26.
Score: 0.040
-
Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem. 1999 Jan 15; 274(3):1646-56.
Score: 0.009
-
Ghosh S, Zheng Y, Jun X, Narla RK, Mahajan S, Navara C, Mao C, Sudbeck EA, Uckun FM. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin Cancer Res. 1998 Nov; 4(11):2657-68.
Score: 0.009